<DOC>
	<DOCNO>NCT00640406</DOCNO>
	<brief_summary>The clinical investigation prospective , international , multi-centre , randomize ( 1:1 ) trial follow ups 2 , 6 , 12 month 3 year . The purpose study evaluate clinical impact percutaneous transluminal renal artery stenting ( PTRAS ) impair renal function measure estimate Glomerular Filtration Rate ( eGFR ) patient hemodynamically significant atherosclerotic renal artery stenosis ( ARAS ) .</brief_summary>
	<brief_title>Comparison Best Medical Treatment Versus Best Medical Treatment Plus Renal Artery Stenting</brief_title>
	<detailed_description />
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Renal Artery Obstruction</mesh_term>
	<criteria>Age ≥ 18 year Informed consent sign patient ( and/or legal guardian ) , Hemodynamically relevant de novo unilateral bilateral atherosclerotic renal artery diameter stenosis RAS ( ≥ 70 % ) Estimated GFR &gt; 10 ml/min calculate use abbreviate Modification Diet Renal Disease ( MDRD ) Study equation , Patients present mild , moderate severe hypertension ( define accord WHO guideline ) and/or renal dysfunction , Target lesion must completely coverable one study stent , Total target lesion length estimate less 19 mm , Target lesion accessible direct stenting , predilation , likely sufficiently benefit stenting ( discretion investigator ) , Renal reference vessel diameter ( RVD ) ≥ 4.0 mm &lt; 7.0 mm base visual estimation , Willingness comply specify followup evaluation . Estimated GFR ≤ 10 ml/min , Renal atrophy kidney length &lt; 7cm ( refer kidney target lesion ) , Patient eligible PTRAS , Patient eligible stenting , Target lesion occlusion , Target lesion and/or target vessel proximal target lesion severely calcify , Treatment branch lesion require , Fresh thrombus embolic lesion Need embolic protection previous plan PTRAS , Clotting disorder , INR &gt; 2.5 intervention , Patient present fibromuscular dysplasia , Prior revascularization target lesion , History target vessel revascularization within last six month , Angiographic restenosis segment target vessel undergone prior percutaneous intervention , Any thrombolytic therapy procedure within 72 hour prior plan study procedure Active peptic ulcer gastro intestinal bleeding , Active inflammation kidney interfere diagnosis treatment RAS ( e.g . glomerulonephritis , aortitis , vasculitis ) , Radiation damage kidney , Renal disease associate aortic aneurysm i.e . diameter aorta &gt; 40 mm , Chronic renal replacement therapy , Life expectancy &lt; 1 year , Comorbid condition limit participation followup Patient currently participate another trial possibly influence safety patient and/or outcome study , Pregnancy/Planned pregnancy/Childbearing potential without sufficient measure prevent pregnancy judge investigator , Known allergy contrast medium adequately control premedication , Known intolerance acetylicsalicylic acid ( ASA ) , heparin , clopidogrel ticlopidin , cobaltchromium , Metformin intake stop least 48 hour intervention</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>